How High Will Airbnb Stock Go?
Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…
Buy
51
AMTX Quote, Financials, Valuation and Earnings
Last price:
$2.87
Seasonality move
:
56.22%
Day range:
$2.60 - $2.90
52-week range:
$2.10 - $7.03
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.43x
P/B ratio:
--
Volume:
913.1K
Avg. volume:
729.2K
1-year change:
-51.28%
Market cap:
$142.2M
Revenue:
$186.7M
EPS (TTM):
-$2.26
Analysts' Opinion
-
Consensus RatingAemetis has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $11.75, Aemetis has an estimated upside of 310.84% from its current price of $2.86.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.00 representing 100% downside risk from its current price of $2.86.
Fair Value
-
According to the consensus of 4 analysts, Aemetis has 310.84% upside to fair value with a price target of $11.75 per share.
AMTX vs. S&P 500
-
Over the past 5 trading days, Aemetis has overperformed the S&P 500 by 3.86% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Aemetis does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Aemetis has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Aemetis reported revenues of $81.4M.
Earnings Growth
-
Aemetis has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Aemetis reported earnings per share of -$0.38.
Enterprise value:
464.2M
EV / Invested capital:
7.33x
Price / LTM sales:
0.43x
EV / EBIT:
--
EV / Revenue:
1.59x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-32.27x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$2.3M
Return On Assets:
-38.94%
Net Income Margin (TTM):
-33.21%
Return On Equity:
--
Return On Invested Capital:
-133.41%
Operating Margin:
-4.75%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $254.1M | $182.7M | $291.4M | $68.7M | $81.4M | |
| Gross Profit | $8.3M | $21K | $2.3M | $492K | $3.9M | |
| Operating Income | -$20.5M | -$37.1M | -$35.9M | -$8.5M | -$3.9M | |
| EBITDA | -$55.2M | -$35.2M | -$33.4M | -$6.4M | -$2M | |
| Diluted EPS | -$2.50 | -$1.31 | -$2.26 | $0.73 | -$0.38 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $13.5M | $17M | $24.1M | $78.5M | $34.9M | |
| Total Assets | $122.2M | $147M | $198.9M | $277.4M | $247.4M | |
| Current Liabilities | $95.8M | $74.6M | $183.1M | $114.4M | $132.2M | |
| Total Liabilities | $297.7M | $279.1M | $383.8M | $477.4M | $506.3M | |
| Total Equity | -$175.6M | -$132.1M | -$184.9M | -$200M | -$258.9M | |
| Total Debt | $226.3M | $185M | $223M | $286.5M | $322.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$17M | -$26.7M | $13.6M | -$6.2M | -$5M | |
| Cash From Investing | -$26.9M | -$20.7M | -$23.2M | -$8.4M | -$4.5M | |
| Cash From Financing | $37.7M | $54.8M | $5.3M | $16.4M | $9.1M | |
| Free Cash Flow | -$53.8M | -$55.5M | -$14.4M | -$14.9M | -$9.5M | |
AMTX
Sector
Market Cap
$142.2M
$66.3M
Price % of 52-Week High
40.68%
62.32%
Dividend Yield
0%
0%
Shareholder Yield
-35.94%
5.21%
1-Year Price Total Return
-51.28%
-20.65%
Beta (5-Year)
1.352
1.065
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$2.75
200-day SMA
Sell
Level
$3.33
Bollinger Bands (100)
Sell
Level
2.34 - 3.44
Chaikin Money Flow
Sell
Level
-85.6M
20-day SMA
Sell
Level
$3.16
Relative Strength Index (RSI14)
Sell
Level
41.66
ADX Line
Buy
Level
11.81
Williams %R
Neutral
Level
-62.3656
50-day SMA
Sell
Level
$3.27
MACD (12, 26)
Sell
Level
-0.22
25-day Aroon Oscillator
Sell
Level
-76
On Balance Volume
Neutral
Level
479.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.4915)
Sell
CA Score
(Annual)
Level (-7.5412)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (11.643)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Aemetis Inc is an renewable fuel and biochemicals company focused on the production of renewable fuels and chemicals through the acquisition, development and commercialization of technologies that replace traditional petroleum-based products through the conversion of first-generation ethanol and biodiesel plants into advanced biorefineries. It owns and operates an approximately 65 million gallon per year ethanol production facility located in Keyes, California. In addition to low carbon renewable fuel ethanol, the Keyes Plant produces Wet Distillers Grains, Distillers Corn Oil, and Condensed Distillers Solubles, all of which are sold to local dairies and feedlots as animal feed. It operates in the reportable geographic segments of North America and India.
Stock Forecast FAQ
In the current month, AMTX has received 2 Buy ratings 2 Hold ratings, and 0 Sell ratings. The AMTX average analyst price target in the past 3 months is $11.75.
-
Where Will Aemetis Stock Be In 1 Year?
According to analysts, the consensus estimate is that Aemetis share price will rise to $11.75 per share over the next 12 months.
-
What Do Analysts Say About Aemetis?
Analysts are divided on their view about Aemetis share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Aemetis is a Sell and believe this share price will drop from its current level to $3.00.
-
What Is Aemetis's Price Target?
The price target for Aemetis over the next 1-year time period is forecast to be $11.75 according to 4 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is AMTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Aemetis is a Leans Bullish. 2 of 4 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of AMTX?
You can purchase shares of Aemetis via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Aemetis shares.
-
What Is The Aemetis Share Price Today?
Aemetis was last trading at $2.87 per share. This represents the most recent stock quote for Aemetis. Yesterday, Aemetis closed at $2.86 per share.
-
How To Buy Aemetis Stock Online?
In order to purchase Aemetis stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 43x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
57
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
64
ARQQ alert for Dec 27
Arqit Quantum [ARQQ] is up 49.85% over the past day.
Buy
64
QMCO alert for Dec 27
Quantum [QMCO] is up 49.62% over the past day.
Buy
65
ALGS alert for Dec 27
Aligos Therapeutics [ALGS] is up 10.88% over the past day.
